Phenominer Database Results (276 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
BDIX/CrCrl mean platelet volume DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 56 days 20 5.8 fl 0.02 0.1 automated hematology analysis 0.0 0 um^3 107820 3097
BDIX/CrCrl total white blood cell count DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity male 56 days 20 10.7 x 1000 cells/ul 0.02 0.1 automated total white blood cell count test 0.0 0 WBC 107825 3097
BDIX/CrCrl mean platelet volume DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 5.8 fl 0.03 0.1 automated hematology analysis 0.0 0 107824 3097
BDIX/CrCrl total white blood cell count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity male 92 days 10 8.5 x 1000 cells/ul 0.0 0.0 automated total white blood cell count test 0.0 0 WBC 107829 3097
BDIX/CrCrl blood hemoglobin level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 18.9 g/dl 0.47 1.5 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107833 3097
BDIX/CrCrl red blood cell distribution width-coefficient of variation DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 92 days 10 17.0 % 0.22 0.7 automated hematology analysis 0.0 0 MCV, RDW% 107849 3097
BDIX/CrCrl blood lymphocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 56 days 20 6.8 % 0.02 0.1 automated differential white blood cell count test 0.0 0 LYM 107850 3097
BDIX/CrCrl serum total cholesterol level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount male 92 days 10 48.0 mg/dl 0.0 0.0 automated serum analysis 0.0 0 serum total cholesterol 107895 3097
BDIX/CrCrl blood lymphocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 92 days 10 6.1 % 0.09 0.3 automated differential white blood cell count test 0.0 0 LYM 107854 3097
BDIX/CrCrl blood lymphocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 92 days 10 8.0 % 0.09 0.3 automated differential white blood cell count test 0.0 0 LYM 107853 3097
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 16 1.17 x 10E6 cells/ml 0.07 0.3 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111098 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 0.69 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111101 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 21 2.1 x 10E6 cells/ml 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111105 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 2267.0 cells/ul 74.25 315.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111093 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 16 1631.0 cells/ul 149.75 599.0 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111088 3196
BDIX/CrCrl red blood cell count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 71 days 10 11.0 x 10E6 cells/ul 0.41 1.3 automated blood cell counting method 0.0 0 red blood cell count, hematocrit 107801 3097
BDIX/CrCrl red blood cell count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 71 days 10 11.0 x 10E6 cells/ul 0.09 0.3 automated blood cell counting method 0.0 0 red blood cell count, hematocrit 107802 3097
BDIX/CrCrl mean corpuscular volume DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 56 days 20 47.1 fl 0.02 0.1 automated hematology analysis 0.0 0 MCV, RDW% 107805 3097
BDIX/CrCrl mean corpuscular volume DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 71 days 10 47.8 fl 0.25 0.8 automated hematology analysis 0.0 0 MCV, RDW% 107807 3097
BDIX/CrCrl hematocrit DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 71 days 10 52.3 % 0.95 3.0 hematocrit analysis 0.0 0 red blood cell count, hematocrit 107811 3097
BDIX/CrCrl hematocrit DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 71 days 10 52.7 % 0.7 2.2 hematocrit analysis 0.0 0 red blood cell count, hematocrit 107812 3097
BDIX/CrCrl hematocrit DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 92 days 10 44.0 % 0.98 3.1 hematocrit analysis 0.0 0 red blood cell count, hematocrit 107814 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-163 days 18 median 99.7 d 4.38 18.6 necropsy 0.0 0 two treatment fluorouracil 5-FU 111143 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-164 days 18 median 101.3 d 3.87 16.4 necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111144 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % 0.0 0.0 necropsy 0.0 0 saline control group 111124 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 0.96 x 1000 cells/ul 0.06 0.25 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111110 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-186 days 21 9.5 % necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111157 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 44.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + interleukin-2 111148 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 21 9.5 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111153 3196
BDIX/CrCrl serum aspartate aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount male 71 days 10 139.0 U/l 2.59 8.2 automated serum analysis 0.0 0 serum aspartate aminotransferase 107902 3097
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.21 cm3 0.58 2.01 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 110995 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.09 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 110997 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2839.0 % 502.0 1738.98 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 111005 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2039.0 % 562.0 1946.83 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 111004 3191
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111165 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111167 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111171 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111172 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111175 3195
BDIX/CrCrl blood lymphocyte count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 71 days 10 65.5 x 1000 cells/ul 0.38 1.2 automated differential white blood cell count test 0.0 0 LYM 107862 3097
BDIX/CrCrl blood lymphocyte count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 71 days 10 62.8 x 1000 cells/ul 0.32 1.0 automated differential white blood cell count test 0.0 0 LYM 107861 3097
BDIX/CrCrl blood granulocyte count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 71 days 10 8.7 x 1000 cells/ul 0.25 0.8 automated differential white blood cell count test 0.0 0 107867 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-162 days 15 median 98.7 d 2.17 8.4 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111123 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment interleukin-2 111135 3196
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 237.0 % 19.6 67.9 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110815 3191
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 58.6 % 8.2 28.41 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days portal vein occlusion group POD30 portal vein occlusion group POD30 110820 3191
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111161 3195
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.7 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 24 days 30% hepatectomy group POD17 30% hepatectomy group POD17 110822 3191
BDIX/CrCrl metastatic lung tumor area measurement DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) and taurolidine (2 %) (for 7 days) then control condition (for 14 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 3290368.2 um2 ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis size, um^2 lung metastasis %, number, and size 107110 3076
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group B 111029 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 40.0 % 0.0 0.0 necropsy 0.0 30 days group 3 111033 3195
BDIX/CrCrl serum amylase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount male 71 days 10 3089.0 U/l 38.58 122.0 automated serum analysis 0.0 0 serum amylase 107945 3097
BDIX/CrCrl total white blood cell count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity male 71 days 10 12.4 x 1000 cells/ul 0.22 0.7 automated total white blood cell count test 0.0 0 WBC 107827 3097
BDIX/CrCrl blood hemoglobin level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 16.6 g/dl 0.32 1.0 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107834 3097
BDIX/CrCrl blood hemoglobin level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 20.1 g/dl 0.28 0.9 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107832 3097
BDIX/CrCrl mean corpuscular hemoglobin DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 18.3 pg 0.13 0.4 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107837 3097
BDIX/CrCrl mean corpuscular hemoglobin concentration DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 38.0 g/dl 0.13 0.4 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107841 3097
BDIX/CrCrl red blood cell distribution width-coefficient of variation DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 71 days 10 16.9 % 0.16 0.5 automated hematology analysis 0.0 0 MCV, RDW% 107847 3097
BDIX/CrCrl red blood cell distribution width-coefficient of variation DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 92 days 10 17.7 % 0.13 0.4 automated hematology analysis 0.0 0 MCV, RDW% 107848 3097
BDIX/CrCrl blood lymphocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 71 days 10 8.0 % 0.13 0.4 automated differential white blood cell count test 0.0 0 LYM 107852 3097
BDIX/CrCrl serum triglyceride level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 ml/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount male 92 days 10 252.0 mg/dl 10.21 32.3 automated serum analysis 0.0 0 serum triglyceride level 107900 3097
BDIX/CrCrl serum triglyceride level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount male 92 days 10 249.0 mg/dl 6.96 22.0 automated serum analysis 0.0 0 serum triglyceride level 107899 3097
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 77 days-91 days 16 2.25 x 10E6 cells/ml 0.18 0.72 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111097 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 16 0.92 x 10E6 cells/ml 0.03 0.1 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111099 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 111 days-125 days 18 1.23 x 10E6 cells/ml 0.05 0.23 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111103 3196
BDIX/CrCrl platelet distribution width DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 8.6 fl 0.03 0.1 automated hematology analysis 0.0 0 107884 3097
BDIX/CrCrl serum urea nitrogen level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount male 71 days 10 35.0 mg/dl 0.57 1.8 automated serum analysis 0.0 0 serum BUN 107887 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 77 days-91 days 16 2294.0 cells/ul 205.0 820.0 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111087 3196
BDIX/CrCrl hematocrit DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 56 days 20 47.6 % 0.02 0.1 hematocrit analysis 0.0 0 red blood cell count, hematocrit 107810 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 82.7 d 3.87 15.0 necropsy 0.0 28 one treatment fluorouracil 5-FU 111117 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-140 days 14 median 77.4 d 6.95 26.0 necropsy 0.0 0 one treatment thymosin alpha-1 111118 3196
BDIX/CrCrl red blood cell count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 92 days 10 10.7 x 10E6 cells/ul 0.25 0.8 automated blood cell counting method 0.0 0 red blood cell count, hematocrit 107803 3097
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 0.3 x 1000 cells/ul 0.08 0.36 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111111 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 18 2.22 x 1000 cells/ul 0.06 0.26 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2 111113 3196
BDIX/CrCrl serum total bilirubin level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount male 92 days 10 0.35 mg/dl 0.16 0.5 automated serum analysis 0.0 0 serum bilirubin 107926 3097
BDIX/CrCrl serum lactate dehydrogenase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount male 71 days 10 682.0 U/l 31.94 101.0 automated serum analysis 0.0 0 107930 3097
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 21 81.0 % in vivo visual assessment 0.0 100 days two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111149 3196
BDIX/CrCrl serum triglyceride level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount male 71 days 10 265.0 mg/dl 8.22 26.0 automated serum analysis 0.0 0 serum triglyceride level 107897 3097
BDIX/CrCrl serum aspartate aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount male 92 days 10 193.0 U/l 8.22 26.0 automated serum analysis 0.0 0 serum aspartate aminotransferase 107904 3097
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.67 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 110994 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.3 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 110996 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 725.0 % 151.0 523.08 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 111002 3191
BDIX/CrCrl serum amylase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount male 92 days 10 3190.0 U/l 77.16 244.0 automated serum analysis 0.0 0 serum amylase 107946 3097
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.8 mm 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111079 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111166 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111170 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111168 3195
BDIX/CrCrl blood granulocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 56 days 20 1.1 % 0.0 0.0 automated differential white blood cell count test 0.0 0 107855 3097
BDIX/CrCrl blood granulocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 71 days 10 1.2 % 0.0 0.0 automated differential white blood cell count test 0.0 0 107856 3097
BDIX/CrCrl blood lymphocyte count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 92 days 10 72.0 x 1000 cells/ul 1.36 4.3 automated differential white blood cell count test 0.0 0 LYM 107864 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-142 days 13 median 78.5 d 3.63 13.1 necropsy 0.0 14 saline saline control group 111116 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 100.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111129 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % necropsy 0.0 0 saline control group 111132 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111130 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 87.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111137 3196
BDIX/CrCrl platelet distribution width (percentage) DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 8.5 % 0.0 0.0 automated hematology analysis 0.0 0 108148 3097
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111169 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111174 3195
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 12.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111058 3195
BDIX/CrCrl serum triglyceride level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount male 56 days 20 248.0 mg/dl 5.59 25.0 automated serum analysis 0.0 0 serum triglyceride level 107896 3097
BDIX/CrCrl percentage of study population displaying metastatic tumors in the lung at a point in time DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) and taurolidine (2 %) (for 7 days) then control condition (for 14 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 60.0 % ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis % lung metastasis %, number, and size 107100 3076
BDIX/CrCrl metastatic lung tumor number DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) and taurolidine (2 %) (for 7 days) then control condition (for 14 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 18.2 null ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis number lung metastasis %, number, and size 107105 3076
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group A 111028 3195
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 1 111031 3195
BDIX/CrCrl serum alkaline phosphatase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount male 92 days 10 596.0 U/l 2.91 9.2 automated serum analysis 0.0 0 serum alkaline phosphatase 107915 3097
BDIX/CrCrl serum alanine aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount male 92 days 10 52.0 U/l 3.07 9.7 automated serum analysis 0.0 0 serum alanine aminotransferase 107910 3097
BDIX/CrCrl serum total bilirubin level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount male 71 days 10 0.3 mg/dl 0.0 0.0 automated serum analysis 0.0 0 serum bilirubin 107925 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 21 1215.0 cells/ul 87.07 399.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111094 3196
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.73 cm3 0.21 0.73 magnetic resonance imaging liver 0.0 5 days portal vein occlusion group baseline portal vein occlusion group baseline 110812 3191
BDIX/CrCrl platelet count DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet quantity male 56 days 20 605.0 x 1000 /ul 11.18 50.0 automated platelet count test 0.0 0 platelet, plateletcrit 107815 3097
BDIX/CrCrl mean platelet volume DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 5.9 fl 0.03 0.1 automated hematology analysis 0.0 0 107821 3097
BDIX/CrCrl blood hemoglobin level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 19.9 g/dl 0.66 2.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107831 3097
BDIX/CrCrl mean corpuscular hemoglobin DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 56 days 20 17.9 pg 0.02 0.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107835 3097
BDIX/CrCrl blood hemoglobin level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 56 days 20 18.1 g/dl 0.02 0.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107830 3097
BDIX/CrCrl mean corpuscular hemoglobin concentration DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 56 days 20 38.1 g/dl 0.02 0.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107840 3097
BDIX/CrCrl mean corpuscular hemoglobin DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 17.7 pg 0.22 0.7 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107839 3097
BDIX/CrCrl mean corpuscular hemoglobin concentration DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 37.7 g/dl 0.51 1.6 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107844 3097
BDIX/CrCrl serum total cholesterol level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount male 71 days 10 60.0 mg/dl 2.21 7.0 automated serum analysis 0.0 0 serum total cholesterol 107892 3097
BDIX/CrCrl serum alkaline phosphatase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount male 92 days 10 620.0 U/l 7.27 23.0 automated serum analysis 0.0 0 serum alkaline phosphatase 107914 3097
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 21 2.0 x 10E6 cells/ml 0.11 0.51 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111104 3196
BDIX/CrCrl platelet distribution width DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 8.6 fl 0.09 0.3 automated hematology analysis 0.0 0 107885 3097
BDIX/CrCrl serum urea nitrogen level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount male 92 days 10 34.5 mg/dl 0.41 1.3 automated serum analysis 0.0 0 serum BUN 107889 3097
BDIX/CrCrl serum urea nitrogen level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount male 71 days 10 41.0 mg/dl 0.73 2.3 automated serum analysis 0.0 0 serum BUN 107888 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 16 1917.0 cells/ul 105.25 421.0 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111089 3196
BDIX/CrCrl mean corpuscular volume DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 92 days 10 47.1 fl 0.25 0.8 automated hematology analysis 0.0 0 MCV, RDW% 107809 3097
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 16 1.81 x 1000 cells/ul 0.08 0.32 fluorescence-activated cell sorting method 0.0 28 days saline control saline control group 111108 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 18 1.88 x 1000 cells/ul 0.07 0.29 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111112 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-164 days 18 22.0 % necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111156 3196
BDIX/CrCrl serum total bilirubin level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount male 71 days 10 0.4 mg/dl 0.03 0.1 automated serum analysis 0.0 0 serum bilirubin 107924 3097
BDIX/CrCrl serum total bilirubin level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount male 56 days 20 0.35 mg/dl 0.04 0.2 automated serum analysis 0.0 0 serum bilirubin 107923 3097
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 21 4.5 x 1000 cells/ul 0.23 1.05 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111115 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 16 19.0 % 0.0 0.0 in vivo visual assessment 0.0 100 days two treatment regimen saline control group 111146 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 16 0.0 % in vivo visual assessment 0.0 150 days two treatment regimen saline control group 111150 3196
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatments 5-fluorouracil + interleukin-2 111152 3196
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 472.0 % 127.0 439.94 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110998 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2112.0 % 618.0 2140.81 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 111001 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.32 cm3 0.59 2.04 magnetic resonance imaging liver 0.0 31 days 30% hepatectomy group POD24 30% hepatectomy group POD24 110987 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.63 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 24 days 70% hepatectomy group POD17 70% hepatectomy group POD 17 110821 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.67 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 24 days sham surgical group POD17 sham surgical group POD17 110823 3191
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111158 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111163 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111162 3195
BDIX/CrCrl blood granulocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 71 days 10 1.1 % 0.0 0.0 automated differential white blood cell count test 0.0 0 107857 3097
BDIX/CrCrl blood granulocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 92 days 10 0.8 % 0.0 0.0 automated differential white blood cell count test 0.0 0 107858 3097
BDIX/CrCrl blood granulocyte count DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 56 days 20 8.9 x 1000 cells/ul 0.02 0.1 automated differential white blood cell count test 0.0 0 107865 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-147 days 14 median 84.0 d 3.61 13.5 necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111122 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111136 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111139 3196
BDIX/CrCrl platelet distribution width (percentage) DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 5.2 % 0.0 0.0 automated hematology analysis 0.0 0 108149 3097
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 220.0 % 25.3 87.64 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110816 3191
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.7 cm3 0.83 2.88 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110813 3191
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 22.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111060 3195
BDIX/CrCrl serum alkaline phosphatase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount male 71 days 10 476.0 U/l 1.58 5.0 automated serum analysis 0.0 0 serum alkaline phosphatase 107912 3097
BDIX/CrCrl percentage of study population displaying metastatic tumors in the lung at a point in time DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) then taurolidine (2 %) (for 7 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 80.0 % ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis % lung metastasis %, number, and size 107101 3076
BDIX/CrCrl metastatic lung tumor area measurement DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 3 4.56379937E7 um2 ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis size, um^2 lung metastasis %, number, and size 107109 3076
BDIX/CrCrl metastatic lung tumor area measurement DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) then taurolidine (2 %) (for 7 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 3018460.8 um2 ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis size, um^2 lung metastasis %, number, and size 107111 3076
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 10.1 mm 0.03 0.06 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111084 3195
BDIX/CrCrl serum total cholesterol level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount male 56 days 20 48.0 mg/dl 0.18 0.8 automated serum analysis 0.0 0 serum total cholesterol 107891 3097
BDIX/CrCrl serum alanine aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount male 92 days 10 44.8 U/l 2.94 9.3 automated serum analysis 0.0 0 serum alanine aminotransferase 107909 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 21 3664.0 cells/ul 56.74 260.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU +IL-2+ Ta1 111095 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.52 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110990 3191
BDIX/CrCrl platelet count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet quantity male 92 days 10 815.0 x 1000 /ul 2.53 8.0 automated platelet count test 0.0 0 platelet, plateletcrit 107818 3097
BDIX/CrCrl mean platelet volume DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 5.8 fl 0.03 0.1 automated hematology analysis 0.0 0 107822 3097
BDIX/CrCrl mean corpuscular hemoglobin DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 18.0 pg 0.06 0.2 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107836 3097
BDIX/CrCrl mean corpuscular hemoglobin concentration DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 71 days 10 38.2 g/dl 0.03 0.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107842 3097
BDIX/CrCrl mean corpuscular hemoglobin concentration DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 37.0 g/dl 0.19 0.6 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107843 3097
BDIX/CrCrl red blood cell distribution width-coefficient of variation DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 56 days 20 16.4 % 0.02 0.1 automated hematology analysis 0.0 0 MCV, RDW% 107845 3097
BDIX/CrCrl blood lymphocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 71 days 10 8.1 % 0.25 0.8 automated differential white blood cell count test 0.0 0 LYM 107851 3097
BDIX/CrCrl serum triglyceride level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood triglyceride amount male 71 days 10 259.0 mg/dl 9.49 30.0 automated serum analysis 0.0 0 serum triglyceride level 107898 3097
BDIX/CrCrl serum aspartate aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount male 92 days 10 168.0 U/l 4.36 13.8 automated serum analysis 0.0 0 serum aspartate aminotransferase 107905 3097
BDIX/CrCrl serum alanine aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount male 71 days 10 59.2 U/l 1.99 6.3 automated serum analysis 0.0 0 serum alanine aminotransferase 107907 3097
BDIX/CrCrl serum alanine aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount male 56 days 20 57.2 U/l 1.19 5.3 automated serum analysis 0.0 0 serum alanine aminotransferase 107906 3097
BDIX/CrCrl serum alanine aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 ml/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alanine transaminase amount male 71 days 10 53.4 U/l 2.62 8.3 automated serum analysis 0.0 0 serum alanine aminotransferase 107908 3097
BDIX/CrCrl serum alkaline phosphatase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount male 71 days 10 603.0 U/l 2.85 9.0 automated serum analysis 0.0 0 serum alkaline phosphatase 107913 3097
BDIX/CrCrl serum amylase activity level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount male 56 days 20 2996.0 U/l 20.57 92.0 automated serum analysis 0.0 0 serum amylase 107943 3097
BDIX/CrCrl serum amylase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount male 71 days 10 3096.0 U/l 32.26 102.0 automated serum analysis 0.0 0 serum amylase 107944 3097
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 0.43 x 10E6 cells/ml 0.02 0.11 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111100 3196
BDIX/OrlCrl blood CD8 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD8-positive T cell quantity male 91 days-105 days 18 1.1 x 10E6 cells/ml 0.02 0.09 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111102 3196
BDIX/CrCrl platelet distribution width DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 56 days 20 8.5 fl 0.07 0.3 automated hematology analysis 0.0 0 107881 3097
BDIX/CrCrl platelet distribution width DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 8.7 fl 0.16 0.5 automated hematology analysis 0.0 0 107882 3097
BDIX/CrCrl serum urea nitrogen level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount male 56 days 20 36.0 mg/dl 0.38 1.7 automated serum analysis 0.0 0 serum BUN 107886 3097
BDIX/CrCrl platelet distribution width DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 8.7 fl 0.06 0.2 automated hematology analysis 0.0 0 107883 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 987.0 cells/ul 23.81 101.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 111092 3196
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 111 days-125 days 18 641.0 cells/ul 161.46 685.0 fluorescence-activated cell sorting method 0.0 48 days two treatments fluorouracil 5-FU 111091 3196
BDIX/CrCrl mean corpuscular volume DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 71 days 10 47.5 fl 0.03 0.1 automated hematology analysis 0.0 0 MCV, RDW% 107806 3097
BDIX/CrCrl mean corpuscular volume DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 92 days 10 47.5 fl 0.19 0.6 automated hematology analysis 0.0 0 MCV, RDW% 107808 3097
BDIX/CrCrl hematocrit DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 92 days 10 51.0 % 1.04 3.3 hematocrit analysis 0.0 0 red blood cell count, hematocrit 107813 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-146 days 15 median 83.1 d 2.32 9.0 necropsy 0.0 0 one treatment interleukin-2 111119 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-144 days 16 median 80.5 d 3.13 12.5 necropsy 0.0 0 saline control group 111142 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-157 days 15 median 94.0 d 2.63 10.2 necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111120 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.59 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110991 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.79 cm3 0.15 0.52 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 110993 3191
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-144 days 16 100.0 % necropsy 0.0 0 two treatment regimen saline control group 111154 3196
BDIX/CrCrl serum lactate dehydrogenase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount male 71 days 10 964.0 U/l 31.31 99.0 automated serum analysis 0.0 0 107929 3097
BDIX/CrCrl serum lactate dehydrogenase activity level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount male 56 days 20 944.0 U/l 17.66 79.0 automated serum analysis 0.0 0 107928 3097
BDIX/CrCrl serum lactate dehydrogenase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount male 92 days 10 2274.0 U/l 45.85 145.0 automated serum analysis 0.0 0 107932 3097
BDIX/CrCrl serum lactate dehydrogenase activity level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood lactate dehydrogenase amount male 92 days 10 2717.0 U/l 163.17 516.0 automated serum analysis 0.0 0 107931 3097
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-163 days 18 39.0 % in vivo visual assessment 0.0 100 days two treatment fluorouracil 5-FU 111147 3196
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 518.0 % 117.0 405.3 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 111000 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 548.0 % 118.0 408.76 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110999 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.2 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 31 days portal vein occlusion group POD24 portal vein occlusion group POD24 110989 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.41 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 31 days sham surgical group POD24 sham surgical group POD24 110988 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.9 cm3 0.16 0.55 magnetic resonance imaging liver 0.0 24 days portal vein occlusion group POD17 portal vein occlusion group POD17 110824 3191
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.9 mm 0.22 0.5 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111081 3195
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111159 3195
BDIX/CrCrl blood lymphocyte count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 92 days 10 77.7 x 1000 cells/ul 0.63 2.0 automated differential white blood cell count test 0.0 0 LYM 107863 3097
BDIX/CrCrl blood granulocyte count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 71 days 10 8.7 x 1000 cells/ul 0.25 0.8 automated differential white blood cell count test 0.0 0 107866 3097
BDIX/CrCrl blood granulocyte count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 92 days 10 7.4 x 1000 cells/ul 0.09 0.3 automated differential white blood cell count test 0.0 0 107869 3097
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.2 mm 0.31 0.7 ex vivo light microscopy with histochemistry 0.0 30 days group B 111078 3195
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111128 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment interleukin-2 111127 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 111134 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111138 3196
BDIX/OrlCrl metastatic liver tumor number DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. liver integrity trait male 77 days 198 22.0 null laparotomy 0.0 14 days laparotomy (MMO:0000783) 111141 3196
BDIX/CrCrl platelet distribution width (percentage) DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 5.2 % 0.0 0.0 automated hematology analysis 0.0 0 108146 3097
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 55.2 % 6.0 20.78 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days 70% hepatectomy group POD30 70% hepatectomy group POD 30 110817 3191
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.1 cm3 1.07 3.71 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110814 3191
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (2 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 17.0 null 0.89 2.0 ex vivo light microscopy with histochemistry 0.0 30 days group B 111059 3195
BDIX/CrCrl serum alkaline phosphatase activity level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood alkaline phosphatase amount male 56 days 20 486.0 U/l 0.67 3.0 automated serum analysis 0.0 0 serum alkaline phosphatase 107911 3097
BDIX/CrCrl percentage of study population displaying metastatic tumors in the lung at a point in time DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 3 100.0 % ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis %, number, and size 107099 3076
BDIX/CrCrl metastatic lung tumor number DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) then taurolidine (2 %) (for 7 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 5 28.2 null ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis number lung metastasis %, number, and size 107107 3076
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 7.9 mm 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111083 3195
BDIX/OrlCrl large liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 17.7 mm 0.36 0.8 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111085 3195
BDIX/CrCrl serum total cholesterol level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount male 71 days 10 64.0 mg/dl 1.87 5.9 automated serum analysis 0.0 0 serum total cholesterol 107893 3097
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 0.0 % 0.0 0.0 necropsy 0.0 30 days group 2 111032 3195
BDIX/CrCrl serum aspartate aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount male 56 days 20 112.0 U/l 1.86 8.3 automated serum analysis 0.0 0 serum aspartate aminotransferase 107901 3097
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment thymosin alpha-1 111126 3196
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 10.0 null 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111063 3195
BDIX/CrCrl platelet count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet quantity male 71 days 10 556.0 x 1000 /ul 17.39 55.0 automated platelet count test 0.0 0 platelet, plateletcrit 107816 3097
BDIX/CrCrl platelet count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet quantity male 71 days 10 629.0 x 1000 /ul 6.32 20.0 automated platelet count test 0.0 0 platelet, plateletcrit 107817 3097
BDIX/CrCrl platelet count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet quantity male 92 days 10 545.0 x 1000 /ul 12.02 38.0 automated platelet count test 0.0 0 platelet, plateletcrit 107819 3097
BDIX/CrCrl mean platelet volume DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 92 days 10 5.9 fl 0.06 0.2 automated hematology analysis 0.0 0 107823 3097
BDIX/CrCrl total white blood cell count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity male 71 days 10 12.9 x 1000 cells/ul 0.63 2.0 automated total white blood cell count test 0.0 0 WBC 107826 3097
BDIX/CrCrl total white blood cell count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. leukocyte quantity male 92 days 10 10.0 x 1000 cells/ul 0.35 1.1 automated total white blood cell count test 0.0 0 WBC 107828 3097
BDIX/CrCrl mean corpuscular hemoglobin DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood hemoglobin amount male 92 days 10 17.5 pg 0.03 0.1 blood hemoglobin analysis 0.0 0 hemoglobin, MCH, MCHC 107838 3097
BDIX/CrCrl red blood cell distribution width-coefficient of variation DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte size trait male 71 days 10 16.9 % 0.22 0.7 automated hematology analysis 0.0 0 MCV, RDW% 107846 3097
BDIX/CrCrl serum aspartate aminotransferase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood aspartate transaminase amount male 71 days 10 122.0 U/l 2.85 9.0 automated serum analysis 0.0 0 serum aspartate aminotransferase 107903 3097
BDIX/CrCrl serum amylase activity level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood amylase amount male 92 days 10 3522.0 U/l 88.23 279.0 automated serum analysis 0.0 0 serum amylase 107947 3097
BDIX/CrCrl serum urea nitrogen level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood urea nitrogen amount male 92 days 10 30.0 mg/dl 0.73 2.3 automated serum analysis 0.0 0 serum BUN 107890 3097
BDIX/OrlCrl blood CD25 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD25-positive T cell quantity male 91 days-105 days 18 588.0 cells/ul 49.73 211.0 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU 111090 3196
BDIX/CrCrl red blood cell count DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 56 days 20 10.1 x 10E6 cells/ul 0.02 0.1 automated blood cell counting method 0.0 0 10^6/mm^3 red blood cell count, hematocrit 107800 3097
BDIX/CrCrl red blood cell count DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. erythrocyte quantity male 92 days 10 9.3 x 10E6 cells/ul 0.25 0.8 automated blood cell counting method 0.0 0 red blood cell count, hematocrit 107804 3097
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-145 days 15 median 81.7 d 3.87 15.0 necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111121 3196
BDIX/OrlCrl post-insult time of death due to metastatic liver tumors DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 98 days-186 days 21 median 122.6 d 2.42 11.1 necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111145 3196
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.56 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 110992 3191
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 111 days-125 days 16 1.57 x 1000 cells/ul 0.06 0.24 fluorescence-activated cell sorting method 0.0 48 days saline control saline control group 111109 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 77 days-91 days 16 2.76 x 1000 cells/ul 0.24 0.96 fluorescence-activated cell sorting method 0.0 14 days sham saline control group 111107 3196
BDIX/OrlCrl blood CD4 cell count DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. CD4-positive T cell quantity male 91 days-105 days 21 3.39 x 1000 cells/ul 0.16 0.72 fluorescence-activated cell sorting method 0.0 28 days one treatment fluorouracil 5-FU + IL2 +Ta1 111114 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-163 days 18 89.0 % necropsy 0.0 0 two treatment fluorouracil 5-FU 111155 3196
BDIX/CrCrl serum total bilirubin level DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 ml/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood bilirubin amount male 92 days 10 0.4 mg/dl 0.0 0.0 automated serum analysis 0.0 0 serum bilirubin 107927 3097
BDIX/OrlCrl ratio of survivors to total study population during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. life span trait male 77 days-213 days 18 0.0 % in vivo visual assessment 0.0 150 days two treatment fluorouracil 5-FU 111151 3196
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1516.0 % 377.0 1305.97 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 111003 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.78 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 31 days 70% hepatectomy group POD24 70% hepatectomy group POD 24 110986 3191
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.18 0.4 ex vivo light microscopy with histochemistry 0.0 30 days group A 111077 3195
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.22 0.5 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111080 3195
BDIX/OrlCrl number of large metastatic liver tumors in the right liver DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group A 111164 3195
BDIX/OrlCrl small liver metastatic tumorous lesion diameter measurement DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.8 mm 0.18 0.4 ex vivo light microscopy with histochemistry 0.0 30 days group 3 111082 3195
BDIX/OrlCrl number of large metastatic liver tumors in the left liver DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 1.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111173 3195
BDIX/CrCrl blood granulocyte count to total leukocyte count ratio DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 92 days 10 0.7 % 0.0 0.0 automated differential white blood cell count test 0.0 0 107859 3097
BDIX/CrCrl blood lymphocyte count DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. lymphocyte quantity male 56 days 20 64.2 x 1000 cells/ul 0.29 1.3 automated differential white blood cell count test 0.0 0 LYM 107860 3097
BDIX/CrCrl blood granulocyte count DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. granulocyte quantity male 92 days 10 7.3 x 1000 cells/ul 0.03 0.1 automated differential white blood cell count test 0.0 0 107868 3097
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 100.0 % 0.0 0.0 necropsy 0.0 0 one treatment fluorouracil 5-FU 111125 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment fluorouracil 5-FU 111133 3196
BDIX/OrlCrl percentage of study population developing ascites during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111131 3196
BDIX/OrlCrl percentage of study population developing metastatic liver tumors during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. liver integrity trait male 77 days 198 98.4 % laparotomy 0.0 14 days laparotomy (MMO:0000783) all study animals prior to treatments 111140 3196
BDIX/CrCrl platelet distribution width (percentage) DHD/K12/TRb cells (1.5 X 10E6) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 56 days 20 5.4 % 0.07 0.3 automated hematology analysis 0.0 0 108145 3097
BDIX/CrCrl platelet distribution width (percentage) DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. platelet size trait male 71 days 10 5.0 % 0.0 0.0 automated hematology analysis 0.0 0 108147 3097
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 54.7 % 4.5 15.59 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days 30% hepatectomy group POD30 30% hepatectomy group POD30 110818 3191
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.62 cm3 0.29 1.0 magnetic resonance imaging liver 0.0 5 days 70% hepatectomy group baseline 70% hepatectomy group baseline 110811 3191
BDIX/OrlCrl number of large metastatic liver tumors DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 0.0 null 0.0 0.0 ex vivo light microscopy with histochemistry 0.0 30 days group C 111160 3195
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 56.5 % 7.2 24.94 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days sham surgical group POD30 sham surgical group POD30 110819 3191
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 12.0 null 1.34 3.0 ex vivo light microscopy with histochemistry 0.0 30 days group 2 111062 3195
BDIX/OrlCrl number of small metastatic liver tumors DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. liver integrity trait male 0 days 5 11.0 null 0.45 1.0 ex vivo light microscopy with histochemistry 0.0 30 days group 1 111061 3195
BDIX/CrCrl metastatic lung tumor number DHD/K12/TRb cells (1 x 10E6 cells) (for 21 days) Hoksch B, etal., Eur J Cardiothorac Surg. 2009 Dec;36(6):1058-63. doi: 10.1016/j.ejcts.2009.04.065. Epub 2009 Oct 21. lung integrity trait not specified 0 days 3 465.7 null ex vivo light microscopy with immunohistochemistry and digital image analysis 0.0 0 lung metastasis # lung metastasis %, number, and size 107102 3076
BDIX/OrlCrl percentage of study population developing peritoneal carcinomatosis during a period of time DHD/K12/TRb cells (3 X 10E6) Maggiori L, etal., Int J Exp Pathol. 2012 Dec;93(6):414-20. doi: 10.1111/j.1365-2613.2012.00841.x. peritoneum integrity trait male 0 days 5 80.0 % 0.0 0.0 necropsy 0.0 30 days group C 111030 3195
BDIX/CrCrl serum total cholesterol level DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e. blood cholesterol amount male 92 days 10 40.5 mg/dl 1.71 5.4 automated serum analysis 0.0 0 serum total cholesterol 107894 3097